Literature DB >> 30814539

MtDNA population variation in Myalgic encephalomyelitis/Chronic fatigue syndrome in two populations: a study of mildly deleterious variants.

Marianne Venter1, Cara Tomas2, Ilse S Pienaar3,4, Victoria Strassheim2,4, Elardus Erasmus1, Wan-Fai Ng2,5, Neil Howell6, Julia L Newton4,5, Francois H Van der Westhuizen1, Joanna L Elson7,8.   

Abstract

Myalgic Encephalomyelitis (ME), also known as Chronic Fatigue Syndrome (CFS) is a debilitating condition. There is growing interest in a possible etiologic or pathogenic role of mitochondrial dysfunction and mitochondrial DNA (mtDNA) variation in ME/CFS. Supporting such a link, fatigue is common and often severe in patients with mitochondrial disease. We investigate the role of mtDNA variation in ME/CFS. No proven pathogenic mtDNA mutations were found. We then investigated population variation. Two cohorts were analysed, one from the UK (n = 89 moderately affected; 29 severely affected) and the other from South Africa (n = 143 moderately affected). For both cohorts, ME/CFS patients had an excess of individuals without a mildly deleterious population variant. The differences in population variation might reflect a mechanism important to the pathophysiology of ME/CFS.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30814539      PMCID: PMC6393470          DOI: 10.1038/s41598-019-39060-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  42 in total

1.  Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups.

Authors:  Corinna Herrnstadt; Joanna L Elson; Eoin Fahy; Gwen Preston; Douglass M Turnbull; Christen Anderson; Soumitra S Ghosh; Jerrold M Olefsky; M Flint Beal; Robert E Davis; Neil Howell
Journal:  Am J Hum Genet       Date:  2002-04-05       Impact factor: 11.025

2.  Mitochondrial DNA as a risk factor for false positives in case-control association studies.

Authors:  Antonio Salas; Joanna L Elson
Journal:  J Genet Genomics       Date:  2015-03-17       Impact factor: 4.275

3.  An evolutionary perspective on pathogenic mtDNA mutations: haplogroup associations of clinical disorders.

Authors:  Corinna Herrnstadt; Neil Howell
Journal:  Mitochondrion       Date:  2004-10-01       Impact factor: 4.160

Review 4.  Metabolic abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a mini-review.

Authors:  Cara Tomas; Julia Newton
Journal:  Biochem Soc Trans       Date:  2018-04-17       Impact factor: 5.407

5.  Mitochondrial DNA haplogroups and risk of transient ischaemic attack and ischaemic stroke: a genetic association study.

Authors:  Patrick F Chinnery; Hannah R Elliott; Anila Syed; Peter M Rothwell
Journal:  Lancet Neurol       Date:  2010-03-31       Impact factor: 44.182

6.  A novel G3337A mitochondrial ND1 mutation related to cardiomyopathy co-segregates with tRNALeu(CUN) A12308G and tRNAThr C15946T mutations.

Authors:  Emily Zifa; Paschalis Theotokis; Archontia Kaminari; Helen Maridaki; Helen Leze; Efrosini Petsiava; Zissis Mamuris; Constantinos Stathopoulos
Journal:  Mitochondrion       Date:  2008-05-27       Impact factor: 4.160

7.  A proposed consensus panel of organisms for determining evolutionary conservation of mt-tRNA point mutations.

Authors:  John W Yarham; Robert McFarland; Robert W Taylor; Joanna L Elson
Journal:  Mitochondrion       Date:  2012-07-07       Impact factor: 4.160

8.  Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease.

Authors:  Gráinne S Gorman; Andrew M Schaefer; Yi Ng; Nicholas Gomez; Emma L Blakely; Charlotte L Alston; Catherine Feeney; Rita Horvath; Patrick Yu-Wai-Man; Patrick F Chinnery; Robert W Taylor; Douglass M Turnbull; Robert McFarland
Journal:  Ann Neurol       Date:  2015-03-28       Impact factor: 10.422

9.  HaploGrep 2: mitochondrial haplogroup classification in the era of high-throughput sequencing.

Authors:  Hansi Weissensteiner; Dominic Pacher; Anita Kloss-Brandstätter; Lukas Forer; Günther Specht; Hans-Jürgen Bandelt; Florian Kronenberg; Antonio Salas; Sebastian Schönherr
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

10.  Mitochondrial DNA variants correlate with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome.

Authors:  Paul Billing-Ross; Arnaud Germain; Kaixiong Ye; Alon Keinan; Zhenglong Gu; Maureen R Hanson
Journal:  J Transl Med       Date:  2016-01-20       Impact factor: 5.531

View more
  10 in total

1.  Genetic risk factors of ME/CFS: a critical review.

Authors:  Joshua J Dibble; Simon J McGrath; Chris P Ponting
Journal:  Hum Mol Genet       Date:  2020-09-30       Impact factor: 6.150

2.  Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations.

Authors:  Alexandra H Mandarano; Jessica Maya; Ludovic Giloteaux; Daniel L Peterson; Marco Maynard; C Gunnar Gottschalk; Maureen R Hanson
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 3.  A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease.

Authors:  Sean Holden; Rebekah Maksoud; Natalie Eaton-Fitch; Hélène Cabanas; Donald Staines; Sonya Marshall-Gradisnik
Journal:  J Transl Med       Date:  2020-07-29       Impact factor: 5.531

4.  A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome.

Authors:  Ruud P H Raijmakers; Anne F M Jansen; Stephan P Keijmel; Rob Ter Horst; Megan E Roerink; Boris Novakovic; Leo A B Joosten; Jos W M van der Meer; Mihai G Netea; Chantal P Bleeker-Rovers
Journal:  J Transl Med       Date:  2019-05-14       Impact factor: 5.531

Review 5.  Metabolomics in Central Sensitivity Syndromes.

Authors:  Joseph S Miller; Luis Rodriguez-Saona; Kevin V Hackshaw
Journal:  Metabolites       Date:  2020-04-24

Review 6.  A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome.

Authors:  Rebekah Maksoud; Cassandra Balinas; Sean Holden; Hélène Cabanas; Donald Staines; Sonya Marshall-Gradisnik
Journal:  J Transl Med       Date:  2021-02-17       Impact factor: 5.531

7.  Experiences of Living with Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.

Authors:  Victoria Strassheim; Julia L Newton; Tracy Collins
Journal:  Healthcare (Basel)       Date:  2021-02-05

Review 8.  Molecular Hydrogen as a Medical Gas for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Possible Efficacy Based on a Literature Review.

Authors:  Shin-Ichi Hirano; Yusuke Ichikawa; Bunpei Sato; Yoshiyasu Takefuji; Fumitake Satoh
Journal:  Front Neurol       Date:  2022-04-11       Impact factor: 4.086

9.  Mitochondrial DNA variation in Parkinson's disease: Analysis of "out-of-place" population variants as a risk factor.

Authors:  Amica C Müller-Nedebock; Abigail L Pfaff; Ilse S Pienaar; Sulev Kõks; Francois H van der Westhuizen; Joanna L Elson; Soraya Bardien
Journal:  Front Aging Neurosci       Date:  2022-07-14       Impact factor: 5.702

10.  Substrate utilisation of cultured skeletal muscle cells in patients with CFS.

Authors:  Cara Tomas; Joanna L Elson; Julia L Newton; Mark Walker
Journal:  Sci Rep       Date:  2020-10-26       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.